The abstract is read at the publisher; the summary is JClub's.
In a prospective trial of EGFR-mutant lung adenocarcinoma patients with TP53/RB1 deficiency, 5 of 11 still transformed to SCLC despite first-line osimertinib plus platinum and etoposide.
- Why it matters: Histologic transformation to SCLC is an aggressive resistance route after EGFR inhibitor success, and its biology in high-risk patients is not well defined.
- What they did: Patients with EGFR+ LUAD at high risk of transformation (TP53/RB1-deficient) received first-line osimertinib with platinum and etoposide, and samples were profiled using genomic and single-cell transcriptomic analyses.
- The result: Transformation was linked to clinical and subclinical plasticity tied to progressive RB pathway disruption, altered chromatin accessibility, and transcriptional programs including neuronal differentiation and epithelial-to-mesenchymal transition, intensified by osimertinib.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.